An AACR Special Conference
Addressing Critical Questions in Ovarian Cancer Research and Treatment

October 1-4, 2017
Wyndham Grand Pittsburgh Downtown
Pittsburgh, Pennsylvania

Sunday, October 1

Welcome Remarks and Opening Keynote Lecture
6:15 p.m.–7:30 p.m.

Welcome Remarks
Title to be announced
Joan S. Brugge, Harvard Medical School, Boston, Massachusetts

Opening Reception
7:30 p.m.–9:30 p.m.

Monday, October 2

Continental Breakfast / Networking Roundtables
7:00 a.m.–8:00 a.m.

Plenary Session 1: DNA Damage and Repair
8:00 a.m.–10:00 a.m.

PARP inhibitors as single agents and in combinations for ovarian cancer: What lies ahead?
Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, Massachusetts

Overcoming the PARP inhibitor resistance in BRCA-deficient ovarian cancers
Lee Zou, MGH Cancer Center/Harvard Medical School, Boston, Massachusetts

Mitotic progression connects DNA damage to activation of anti-tumor immune responses
Roger A. Greenberg, University of Pennsylvania, Philadelphia, Pennsylvania

2 short talks from proffered abstracts

Break
10:00 a.m.–10:30 a.m.

Plenary Session 2: Metabolic Changes in Ovarian Cancer
10:30 a.m.–12:30 p.m.

Title to be announced
Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, Texas

Metabolic changes in stromal and tumor cells at the metastatic site
Ernst R. Lengyel, University of Chicago, Chicago, Illinois

Title to be announced
Silencing PFKFB2 enhances paclitaxel sensitivity by modulating metabolism of p53 WT ovarian and breast cancer cells and xenografts
Zhen Lu, The University of Texas MD Anderson Cancer Center, Houston, Texas

1 short talks from proffered abstracts

Free Time (Lunch on Own)
12:30 p.m.–3:00 p.m.

Plenary Session 3: Tumor Microenvironment
3:00 p.m.–5:00 p.m.

New directions in tumor microenvironment
Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas

Deconstructing and reconstructing ovarian cancer metastases
Frances R. Balkwill, Barts Cancer Institute, London, England

Translating preclinical observations into trials addressing changes in the tumor microenvironment
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, Texas

2 short talks from proffered abstracts

Panel Discussion: Innovative Trial Design
5:00 p.m.–6:00 p.m.

Poster Session A / Reception
6:00 p.m.–8:30 p.m.

Tuesday, October 3

Continental Breakfast / Networking Roundtables
7:00 a.m.–8:00 a.m.

Plenary Session 4: Drug Response and Resistance to Therapy
8:00 a.m.–10:00 a.m.

Title to be announced
David D. L. Bowtell, Peter MacCallum Cancer Centre, E. Melbourne, VIC, Australia

Systems approach to rational drug therapy
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas

Exploiting synthetic lethality in gynecological cancers
Christopher Lord, Cancer Research UK London Research Institute, London, England

2 short talks from proffered abstracts

Break
10:00 a.m.–10:30 a.m.
Plenary Session 5: Prevention and Early Detection
10:30 a.m.–12:30 p.m.

Title to be announced
Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas

PapGene and PapDREAMing for early detection of ovarian cancer
Ie-Ming Shih, Johns Hopkins Medical Institutes, Baltimore, Maryland

Title to be announced
James D. Brenton, University of Cambridge, Cambridge, England

2 short talks from proffered abstracts

Poster Session B / Lunch
12:30 p.m.–3:00 p.m.

Plenary Session 6: Exploiting Vulnerabilities in Rare Tumors
3:00 p.m.–5:00 p.m.

Progress and future directions in the management of low-grade serous cancer of the ovary
David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston, Texas

Title to be announced
David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

Therapeutic targeting ARID1A mutation in ovarian cancer
Rugang Zhang, The Wistar Institute, Philadelphia, Pennsylvania

Small cell carcinomas of the ovary: Strengths and weaknesses
Douglas A. Levine, New York University, New York, New York

1 short talk from proffered abstracts

Panel: Funding Opportunities and Advocacy Groups
5:00 p.m.–6:00 p.m.

Wednesday, October 4

Continental Breakfast / Networking Roundtables
7:00 a.m.–8:00 a.m.

Plenary Session 7: Immunotherapy
8:00 a.m.–10:00 a.m.

Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy
Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, New York

How does the immune system contend with intratumoral heterogeneity in ovarian cancer?
Brad Nelson, BC Cancer Agency, Vancouver Island, BC, Canada

Translating fundamental immunobiology into adoptive T cell therapy for ovarian cancer
Daniel J. Powell, University of Pennsylvania, Philadelphia, Pennsylvania
Strategies for glycosylation-based immunotargeting of MUC16
David R. Spriggs, Memorial Sloan Kettering Cancer Center, New York, New York

1 short talk from proffered abstracts

Break
10:00 a.m.–10:15 a.m.

Plenary Session 8: Genetics and Molecular Drivers
10:15 a.m.–12:15 p.m.

Replication road blocks in Cyclin E-amplified ovarian cancers
Ronny I. Drapkin, University of Pennsylvania, Philadelphia, Pennsylvania

Functional genetic architecture of serous ovarian cancer
Robert K. Rottapel, Princess Margaret Cancer Centre, Toronto, ON, Canada

Title to be announced
Andy Futreal, The University of Texas MD Anderson Cancer Center, Houston, Texas

2 short talks from proffered abstracts

Departure
12:15 p.m.